Supplementary Data 1 from Uncoupling CD4<sup>+</sup> TIL-Mediated Tumor Killing from JAK-Signaling in Melanoma

Supplementary Data 1 from Uncoupling CD4<sup>+</sup> TIL-Mediated Tumor Killing from JAK-Signaling in Melanoma

<p>CD4+ TILs from melanoma can exert cytotoxic activity against autologous tumor cells (GFP+TCL#17)</p>

-д хадгалсан:

Номзүйн дэлгэрэнгүй
Үндсэн зохиолч:	Arianna Draghi (15126339) (author)
Бусад зохиолчид:	Mario Presti (15132062) (author), Agnete W.P. Jensen (15459533) (author), Christopher A. Chamberlain (15459536) (author), Benedetta Albieri (15459539) (author), Anne-Christine K. Rasmussen (15459542) (author), Mads H. Andersen (15459545) (author), Michael D. Crowther (15459548) (author), Inge Marie Svane (15132083) (author), Marco Donia (15132086) (author)
Хэвлэсэн:	2025
Нөхцлүүд:	Cancer Immuno-oncology Immunology Tumor resistance to immune response Immunotherapy Cellular immunotherapy Checkpoint blockade
Шошгууд:	Шошго нэмэх Шошго байхгүй, Энэхүү баримтыг шошголох эхний хүн болох!

Ижил төстэй зүйлс

Supplementary Data 2 from Uncoupling CD4<sup>+</sup> TIL-Mediated Tumor Killing from JAK-Signaling in Melanoma
-н: Arianna Draghi (15126339)
Хэвлэсэн: (2025)

Supplementary Data 3 from Uncoupling CD4<sup>+</sup> TIL-Mediated Tumor Killing from JAK-Signaling in Melanoma
-н: Arianna Draghi (15126339)
Хэвлэсэн: (2025)

Supplementary Table S1 from Intratumoral CD16<sup>+</sup> Macrophages Are Associated with Clinical Outcomes of Patients with Metastatic Melanoma Treated with Combination Anti-PD-1 and Anti-CTLA-4 Therapy
-н: Hansol Lee (15054787)
Хэвлэсэн: (2025)

Supplementary Table S2 from Intratumoral CD16<sup>+</sup> Macrophages Are Associated with Clinical Outcomes of Patients with Metastatic Melanoma Treated with Combination Anti-PD-1 and Anti-CTLA-4 Therapy
-н: Hansol Lee (15054787)
Хэвлэсэн: (2025)

Supplementary Table S3 from Intratumoral CD16<sup>+</sup> Macrophages Are Associated with Clinical Outcomes of Patients with Metastatic Melanoma Treated with Combination Anti-PD-1 and Anti-CTLA-4 Therapy
-н: Hansol Lee (15054787)
Хэвлэсэн: (2025)

Supplementary Table S4 from Intratumoral CD16<sup>+</sup> Macrophages Are Associated with Clinical Outcomes of Patients with Metastatic Melanoma Treated with Combination Anti-PD-1 and Anti-CTLA-4 Therapy
-н: Hansol Lee (15054787)
Хэвлэсэн: (2025)

CD38CD39 Population DEGs DS1 from A Population of Tumor-Infiltrating CD4<sup>+</sup> T Cells Co-Expressing CD38 and CD39 Is Associated with Checkpoint Inhibitor Resistance
-н: Ankita Mitra (17141783)
Хэвлэсэн: (2025)

Teee Gene Signature DS2 from A Population of Tumor-Infiltrating CD4<sup>+</sup> T Cells Co-Expressing CD38 and CD39 Is Associated with Checkpoint Inhibitor Resistance
-н: Ankita Mitra (17141783)
Хэвлэсэн: (2025)

Teee vs Treg Clusters DEGs DS3 from A Population of Tumor-Infiltrating CD4<sup>+</sup> T Cells Co-Expressing CD38 and CD39 Is Associated with Checkpoint Inhibitor Resistance
-н: Ankita Mitra (17141783)
Хэвлэсэн: (2025)

Supplementary Table 1 from Phase I Study of Androgen Deprivation Therapy in Combination with Anti–PD-1 in Melanoma Patients Pretreated with Anti–PD-1
-н: Caroline Robert (15032672)
Хэвлэсэн: (2025)

Supplementary Table 2 from Phase I Study of Androgen Deprivation Therapy in Combination with Anti–PD-1 in Melanoma Patients Pretreated with Anti–PD-1
-н: Caroline Robert (15032672)
Хэвлэсэн: (2025)

Supplementary Table 3 from Phase I Study of Androgen Deprivation Therapy in Combination with Anti–PD-1 in Melanoma Patients Pretreated with Anti–PD-1
-н: Caroline Robert (15032672)
Хэвлэсэн: (2025)

Supplementary Table 4 from Phase I Study of Androgen Deprivation Therapy in Combination with Anti–PD-1 in Melanoma Patients Pretreated with Anti–PD-1
-н: Caroline Robert (15032672)
Хэвлэсэн: (2025)

Supplementary Table S1 from Activin A–Mediated Polarization of Cancer-Associated Fibroblasts and Macrophages Confers Resistance to Checkpoint Immunotherapy in Skin Cancer
-н: Christine Pich-Bavastro (16509238)
Хэвлэсэн: (2025)

Supplementary Table S2 from Activin A–Mediated Polarization of Cancer-Associated Fibroblasts and Macrophages Confers Resistance to Checkpoint Immunotherapy in Skin Cancer
-н: Christine Pich-Bavastro (16509238)
Хэвлэсэн: (2025)

Supplementary Table S3 from Activin A–Mediated Polarization of Cancer-Associated Fibroblasts and Macrophages Confers Resistance to Checkpoint Immunotherapy in Skin Cancer
-н: Christine Pich-Bavastro (16509238)
Хэвлэсэн: (2025)

Supplementary Table S4 from Activin A–Mediated Polarization of Cancer-Associated Fibroblasts and Macrophages Confers Resistance to Checkpoint Immunotherapy in Skin Cancer
-н: Christine Pich-Bavastro (16509238)
Хэвлэсэн: (2025)

Supplementary Table S5 from Activin A–Mediated Polarization of Cancer-Associated Fibroblasts and Macrophages Confers Resistance to Checkpoint Immunotherapy in Skin Cancer
-н: Christine Pich-Bavastro (16509238)
Хэвлэсэн: (2025)

Supplementary Table S6 from Activin A–Mediated Polarization of Cancer-Associated Fibroblasts and Macrophages Confers Resistance to Checkpoint Immunotherapy in Skin Cancer
-н: Christine Pich-Bavastro (16509238)
Хэвлэсэн: (2025)

Supplementary Table S7 from Activin A–Mediated Polarization of Cancer-Associated Fibroblasts and Macrophages Confers Resistance to Checkpoint Immunotherapy in Skin Cancer
-н: Christine Pich-Bavastro (16509238)
Хэвлэсэн: (2025)

Supplementary Table S2 from Genomic Profiling of Radiation-Induced Sarcomas Reveals the Immunologic Characteristics and Its Response to Immune Checkpoint Blockade
-н: Dong-Chun Hong (16374308)
Хэвлэсэн: (2025)

Supplementary Tables from MYC Overexpression Drives Immune Evasion in Hepatocellular Carcinoma That Is Reversible through Restoration of Proinflammatory Macrophages
-н: Renumathy Dhanasekaran (14962092)
Хэвлэсэн: (2025)

Supplementary Figure S1 from Clinical and Molecular Features of Long-term Response to Immune Checkpoint Inhibitors in Patients with Advanced Non–Small Cell Lung Cancer
-н: Rohit Thummalapalli (17314483)
Хэвлэсэн: (2025)

Supplementary Figure S10 from Clinical and Molecular Features of Long-term Response to Immune Checkpoint Inhibitors in Patients with Advanced Non–Small Cell Lung Cancer
-н: Rohit Thummalapalli (17314483)
Хэвлэсэн: (2025)

Supplementary Figure S11 from Clinical and Molecular Features of Long-term Response to Immune Checkpoint Inhibitors in Patients with Advanced Non–Small Cell Lung Cancer
-н: Rohit Thummalapalli (17314483)
Хэвлэсэн: (2025)

Supplementary Figure S12 from Clinical and Molecular Features of Long-term Response to Immune Checkpoint Inhibitors in Patients with Advanced Non–Small Cell Lung Cancer
-н: Rohit Thummalapalli (17314483)
Хэвлэсэн: (2025)

Supplementary Figure S13 from Clinical and Molecular Features of Long-term Response to Immune Checkpoint Inhibitors in Patients with Advanced Non–Small Cell Lung Cancer
-н: Rohit Thummalapalli (17314483)
Хэвлэсэн: (2025)

Supplementary Figure S14 from Clinical and Molecular Features of Long-term Response to Immune Checkpoint Inhibitors in Patients with Advanced Non–Small Cell Lung Cancer
-н: Rohit Thummalapalli (17314483)
Хэвлэсэн: (2025)

Supplementary Figure S15 from Clinical and Molecular Features of Long-term Response to Immune Checkpoint Inhibitors in Patients with Advanced Non–Small Cell Lung Cancer
-н: Rohit Thummalapalli (17314483)
Хэвлэсэн: (2025)

Supplementary Figure S2 from Clinical and Molecular Features of Long-term Response to Immune Checkpoint Inhibitors in Patients with Advanced Non–Small Cell Lung Cancer
-н: Rohit Thummalapalli (17314483)
Хэвлэсэн: (2025)

Supplementary Figure S3 from Clinical and Molecular Features of Long-term Response to Immune Checkpoint Inhibitors in Patients with Advanced Non–Small Cell Lung Cancer
-н: Rohit Thummalapalli (17314483)
Хэвлэсэн: (2025)

Supplementary Figure S4 from Clinical and Molecular Features of Long-term Response to Immune Checkpoint Inhibitors in Patients with Advanced Non–Small Cell Lung Cancer
-н: Rohit Thummalapalli (17314483)
Хэвлэсэн: (2025)

Supplementary Figure S5 from Clinical and Molecular Features of Long-term Response to Immune Checkpoint Inhibitors in Patients with Advanced Non–Small Cell Lung Cancer
-н: Rohit Thummalapalli (17314483)
Хэвлэсэн: (2025)

Supplementary Figure S6 from Clinical and Molecular Features of Long-term Response to Immune Checkpoint Inhibitors in Patients with Advanced Non–Small Cell Lung Cancer
-н: Rohit Thummalapalli (17314483)
Хэвлэсэн: (2025)

Supplementary Figure S7 from Clinical and Molecular Features of Long-term Response to Immune Checkpoint Inhibitors in Patients with Advanced Non–Small Cell Lung Cancer
-н: Rohit Thummalapalli (17314483)
Хэвлэсэн: (2025)

Supplementary Figure S8 from Clinical and Molecular Features of Long-term Response to Immune Checkpoint Inhibitors in Patients with Advanced Non–Small Cell Lung Cancer
-н: Rohit Thummalapalli (17314483)
Хэвлэсэн: (2025)

Supplementary Figure S9 from Clinical and Molecular Features of Long-term Response to Immune Checkpoint Inhibitors in Patients with Advanced Non–Small Cell Lung Cancer
-н: Rohit Thummalapalli (17314483)
Хэвлэсэн: (2025)

Supplementary Table S3 from Clinical and Molecular Features of Long-term Response to Immune Checkpoint Inhibitors in Patients with Advanced Non–Small Cell Lung Cancer
-н: Rohit Thummalapalli (17314483)
Хэвлэсэн: (2025)

Supplementary Table S4 from Clinical and Molecular Features of Long-term Response to Immune Checkpoint Inhibitors in Patients with Advanced Non–Small Cell Lung Cancer
-н: Rohit Thummalapalli (17314483)
Хэвлэсэн: (2025)

Supplementary Figures from NKG7 Is Required for Optimal Antitumor T-cell Immunity
-н: Xian-Yang Li (15022958)
Хэвлэсэн: (2025)

Cannot write session to /tmp/vufind_sessions/sess_c7ktbk3cgv32i6tufad8ca41e2